A Phase 3 interventional study of ezetimibe and Placebo in Primary Hypercholesterolemia, sponsored by Organon and Co. Completed. Open to participants aged 6 Years to 10 Years. Per ClinicalTrials.gov, last updated 2024-05-21.
Sponsored by Organon and Co · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 98 studies testing ezetimibe in Hypercholesterolemia — 3 open to participants now, 4 under way, 1 of them phase 3. Ezetimibe · Hypercholesterolemia.
Among the 98 studies testing ezetimibe in Hypercholesterolemia, this one is the 52nd largest by enrollment of the 97 interventional ones that give a count, is one of 6 that started in 2009, is one of 50 in phase 3, and was the 58th registered.
1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.
Browse Hypercholesterolemia studies →3 of the 98 studies testing ezetimibe in Hypercholesterolemia are open now, in 5 countries. Recruiting first, the newest first:
Chang Gung Memorial Hospital · Sites in Taiwan
Ages 20–100
Daiichi Sankyo · Sites in Germany, Italy, Spain
Ages 18+
Punjab Institute of Cardology · Sites in Pakistan
Ages 18+
By country, each count listing its studies:
Ezetimibe: first FDA approval 2002 (ZETIA), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.
This study: 6 Years to 10 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
98 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 6 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 138 is above the median of 110 across 976 interventional studies indexed under Hypercholesterolemia.
Median enrollment 148 across the 97 interventional studies. Of the 91 that completed or were terminated, 47 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
76 of 98 have an industry lead sponsor. The 10 most frequent:
This study is registered under Organon and Co, one of the names counted as Organon & Co.. Under that name alone:
Organon and Co is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 23 completed or terminated interventional studies of FDA-regulated products, 18 (78%) have results posted.
91 studies in Hypercholesterolemia by Organon & Co.: none open now, none under way, none of them phase 3. Of 91 finished, 43 (47%) have results posted.
Among the 91 studies in Hypercholesterolemia by Organon & Co., this one is the 60th largest by enrollment of the 81 interventional ones that give a count, is one of 3 that started in 2009, is one of 58 in phase 3, and was the 70th registered.
Organon & Co.’s Hypercholesterolemia studies by the year they started, since 2000.
None of the studies under way reaches primary completion within a year.
Among the 98 studies testing ezetimibe in Hypercholesterolemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Organon & Co.’s 91 in Hypercholesterolemia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine the effect of ezetimibe 10 mg/day compared to placebo on the reduction of low-density lipoprotein cholesterol (LDL-C) from baseline to 12 weeks of treatment in children >=6 to \<=10 years old with primary hypercholesterolemia. The study will also evaluate the effect of ezetimibe on total cholesterol (TC), apolipoprotein B (Apo B), high-density lipoprotein cholesterol (HDL-C), non-HDL-C, and triglycerides (TG). The safety of ezetimibe in this subject population will also be evaluated.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Each subject must not:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ezetimibe 10-mg tablet once daily for 12 weeks
Drug: ezetimibe
Placebo to match ezetimibe 10-mg tablet once daily for 12 weeks
Drug: Placebo
oral tablets: ezetimibe 10 mg once daily for 12 weeks
Also known as: SCH 58235, MK-0653, Zetia
oral tablets: placebo to match ezetimibe 10 mg; administered once daily during the 5-week, single-blind, placebo run-in and diet stabilization period and 12-week double-blind treatment period
Percentage Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Week 12
Serum LDL-C levels calculated at baseline and after 12 weeks of study drug administration. LDL-C were calculated by the method of Friedewald equation, LDL-C = Total Cholesterol (TC) - (High-density lipoprotein cholesterol \[HDL-C\] + triglyceride \[TG\]/5).
Time frame: Baseline and Week 12
Percentage Change From Baseline in Total Cholesterol (TC) at Week 12
Serum TC levels measured using enzymatic methods at baseline and after 12 weeks of study drug administration.
Time frame: Baseline and Week 12
Percentage Change From Baseline in Apolipoprotein B (Apo B) at Week 12
Serum Apo B measured at baseline and after 12 weeks of study drug administration.
Time frame: Baseline and Week 12
Percentage Change From Baseline High-density Lipoprotein Cholesterol (HDL-C) at Week 12
Serum HDL-C levels measured by photometry after precipitation at baseline and after 12 weeks of study drug administration.
Time frame: Baseline and Week 12
Percentage Change From Baseline in Non-HDL-C at Week 12
Serum Non-HDL-C calculated at baseline and after 12 weeks of study drug administration. Non-HDL-C values were calculated as follows: Non-HDL-C (mg/dL) = TC - HDL-C.
Time frame: Baseline and Week 12
Percentage Change From Baseline in Triglycerides (TG) at Week 12
Serum TG levels measured using enzymatic methods at baseline and after 12 weeks of study drug.
Time frame: Baseline and Week 12
Percent Change From Baseline in LDL-C at Week 2
Serum LDL-C levels calculated at baseline and after 2 weeks of study drug administration. LDL-C were calculated by the method of Friedewald equation, LDL-C = Total Cholesterol (TC) - (High-density lipoprotein cholesterol \[HDL-C\] + triglyceride \[TG\]/5).
Time frame: Baseline and Week 2
Percent Change From Baseline in LDL-C at Week 4
Serum LDL-C levels calculated at baseline and after 4 weeks of study drug administration. LDL-C were calculated by the method of Friedewald equation, LDL-C = Total Cholesterol (TC) - (High-density lipoprotein cholesterol \[HDL-C\] + triglyceride \[TG\]/5).
Time frame: Baseline and Week 4
Percent Change From Baseline in LDL-C at Week 8
Serum LDL-C levels calculated at baseline and after 8 weeks of study drug administration. LDL-C were calculated by the method of Friedewald equation, LDL-C = Total Cholesterol (TC) - (High-density lipoprotein cholesterol \[HDL-C\] + triglyceride \[TG\]/5).
Time frame: Baseline and Week 8
Percentage Change From Baseline in TC at Week 2
Serum TC levels measured using enzymatic methods at baseline and after 2 weeks of study drug administration.
Time frame: Baseline and Week 2
Percentage Change From Baseline in TC at Week 4
Serum TC levels measured using enzymatic methods at baseline and after 4 weeks of study drug administration.
Time frame: Baseline and Week 4
Percentage Change From Baseline in TC at Week 8
Serum TC levels measured using enzymatic methods at baseline and after 8 weeks of study drug administration.
Time frame: Baseline and Week 8
Percentage Change From Baseline HDL-C at Week 2
Serum HDL-C levels measured by photometry after precipitation at baseline and after 2 weeks of study drug administration.
Time frame: Baseline and Week 2
Percentage Change From Baseline HDL-C at Week 4
Serum HDL-C levels measured by photometry after precipitation at baseline and after 4 weeks of study drug administration.
Time frame: Baseline and Week 4
Percentage Change From Baseline HDL-C at Week 8
Serum HDL-C levels measured by photometry after precipitation at baseline and after 8 weeks of study drug administration.
Time frame: Baseline and Week 8
Percentage Change From Baseline in Non-HDL-C at Week 2
Serum Non-HDL-C calculated at baseline and after 2 weeks of study drug administration. Non-HDL-C values were calculated as follows: Non-HDL-C (mg/dL) = TC - HDL-C.
Time frame: Baseline and Week 2
Percentage Change From Baseline in Non-HDL-C at Week 4
Serum Non-HDL-C calculated at baseline and after 4 weeks of study drug administration. Non-HDL-C values were calculated as follows: Non-HDL-C (mg/dL) = TC - HDL-C.
Time frame: Baseline and Week 4
Percentage Change From Baseline in Non-HDL-C at Week 8
Serum Non-HDL-C calculated at baseline and after 8 weeks of study drug administration. Non-HDL-C values were calculated as follows: Non-HDL-C (mg/dL) = TC - HDL-C.
Time frame: Baseline and Week 8
Percentage Change From Baseline in TG at Week 2
Serum TG levels measured using enzymatic methods at baseline and after 2 weeks of study drug administration.
Time frame: Baseline and Week 2
Percentage Change From Baseline in TG at Week 4
Serum TG levels measured using enzymatic methods at baseline and after 4 weeks of study drug administration.
Time frame: Baseline and Week 4
Percentage Change From Baseline in TG at Week 8
Serum TG levels measured using enzymatic methods at baseline and after 8 weeks of study drug administration.
Time frame: Baseline and Week 8
Percentage Change From Baseline in Apolipoprotein A-I (Apo A-I) at Week 12
Serum Apo A-I levels measured at baseline and after 12 weeks of study drug administration.
Time frame: Baseline and Week 12
Percentage Change From Baseline in TC:HDL-C Ratio at Week 2
Serum TC:HDL-C Ratio calculated at baseline and after 2 weeks of study drug administration.
Time frame: Baseline and Week 2
Percentage Change From Baseline in TC:HDL-C Ratio at Week 4
Serum TC:HDL-C Ratio calculated at baseline and after 4 weeks of study drug administration.
Time frame: Baseline and Week 4
Percentage Change From Baseline in TC:HDL-C Ratio at Week 8
Serum TC:HDL-C Ratio calculated at baseline and after 8 weeks of study drug administration.
Time frame: Baseline and Week 8
Percentage Change From Baseline in TC:HDL-C Ratio at Week 12
Serum TC:HDL-C Ratio calculated at baseline and after 12 weeks of study drug administration.
Time frame: Baseline and Week 12
Percentage Change From Baseline in LDL-C:HDL-C Ratio at Week 2
Serum LDL-C:HDL-C Ratio calculated at baseline and after 2 weeks of study drug administration.
Time frame: Baseline and Week 2
Percentage Change From Baseline in LDL-C:HDL-C Ratio at Week 4
Serum LDL-C:HDL-C Ratio calculated at baseline and after 4 weeks of study drug administration.
Time frame: Baseline and Week 4
Percentage Change From Baseline in LDL-C:HDL-C Ratio at Week 8
Serum LDL-C:HDL-C Ratio calculated at baseline and after 8 weeks of study drug administration.
Time frame: Baseline and Week 8
Percentage Change From Baseline in LDL-C:HDL-C Ratio at Week 12
Serum LDL-C:HDL-C Ratio calculated at baseline and after 12 weeks of study drug administration.
Time frame: Baseline and Week 12
Percentage Change From Baseline in Apo B:Apo A-I Ratio at Week 12
Serum Apo B:Apo A-I Ratio calculated at baseline and after 12 weeks of study drug administration
Time frame: Baseline and Week 12
Percentage Change From Baseline in High-sensitivity C-reactive Protein (Hs-CRP) at Week 4
Plasma hs-CRP measured at baseline and after 4 weeks of study drug administration.
Time frame: Baseline and Week 4
Percentage Change From Baseline in High-sensitivity C-reactive Protein (Hs-CRP) at Week 12
Plasma hs-CRP measured at baseline and after 12 weeks of study drug administration.
Time frame: Baseline and Week 12
Percent Change From Baseline in Sitosterol at Week 2
Plasma sitosterol measured at baseline and after 2 weeks of study drug administration.
Time frame: Baseline and Week 2
Percentage Change From Baseline in Sitosterol at Week 4
Plasma sitosterol measured at baseline and after 4 weeks of study drug administration.
Time frame: Baseline and Week 4
Percentage Change From Baseline in Sitosterol at Week 8
Plasma sitosterol measured at baseline and after 8 weeks of study drug administration.
Time frame: Baseline and Week 8
Percentage Change From Baseline in Sitosterol at Week 12
Plasma sitosterol measured at baseline and after 12 weeks of study drug administration.
Time frame: Baseline and Week 12
Percentage Change From Baseline in Campesterol at Week 2
Plasma campesterol measured at baseline and after 2 weeks of study drug administration.
Time frame: Baseline and Week 2
Percentage Change From Baseline in Campesterol at Week 4
Plasma campesterol measured at baseline and after 4 weeks of study drug administration.
Time frame: Baseline and Week 4
Percentage Change From Baseline in Campesterol at Week 8
Plasma campesterol measured at baseline and after 8 weeks of study drug administration.
Time frame: Baseline and Week 8
Percentage Change From Baseline in Campesterol at Week 12
Plasma campesterol measured at baseline and after 12 weeks of study drug administration.
Time frame: Baseline and Week 12
Percentage Change From Baseline in Cholestanol at Week 2
Plasma cholestanol measured at baseline and after 2 weeks of study drug administration.
Time frame: Baseline and Week 2
Percentage Change From Baseline in Cholestanol at Week 4
Plasma cholestanol measured at baseline and after 4 weeks of study drug administration.
Time frame: Baseline and Week 4
Percentage Change From Baseline in Cholestanol at Week 8
Plasma cholestanol measured at baseline and after 8 weeks of study drug administration.
Time frame: Baseline and Week 8
Percentage Change From Baseline in Cholestanol at Week 12
Plasma cholestanol measured at baseline and after 12 weeks of study drug administration.
Time frame: Baseline and Week 12
Percentage Change From Baseline in Lathosterol at Week 2
Plasma lathosterol measured at baseline and after 2 weeks of study drug administration.
Time frame: Baseline and Week 2
Percentage Change From Baseline in Lathosterol at Week 4
Plasma lathosterol measured at baseline and after 4 weeks of study drug administration.
Time frame: Baseline and Week 4
Percentage Change From Baseline in Lathosterol at Week 8
Plasma lathosterol measured at baseline and after 8 weeks of study drug administration.
Time frame: Baseline and Week 8
Percentage Change From Baseline in Lathosterol at Week 12
Plasma lathosterol measured at baseline and after 12 weeks of study drug administration.
Time frame: Baseline and Week 12
| Milestone | Ezetimibe | Placebo |
|---|---|---|
| Started | 93 | 45 |
| Completed | 89 | 45 |
| Not completed | 4 | 0 |
| Withdrew: Adverse event | 3 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 |
Serum LDL-C levels calculated at baseline and after 12 weeks of study drug administration. LDL-C were calculated by the method of Friedewald equation, LDL-C = Total Cholesterol (TC) - (High-density lipoprotein cholesterol \[HDL-C\] + triglyceride \[TG\]/5).
| Percent Change | Ezetimibe | Placebo |
|---|---|---|
| Percentage Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Week 12 | -27.70 (-30.80 to -24.59) | -0.95 (-4.94 to 3.04) |
Serum TC levels measured using enzymatic methods at baseline and after 12 weeks of study drug administration.
| Percentage Change | Ezetimibe | Placebo |
|---|---|---|
| Percentage Change From Baseline in Total Cholesterol (TC) at Week 12 | -20.74 (-23.29 to -18.18) | 0.19 (-3.07 to 3.44) |
Serum Apo B measured at baseline and after 12 weeks of study drug administration.
| Percent Change | Ezetimibe | Placebo |
|---|---|---|
| Percentage Change From Baseline in Apolipoprotein B (Apo B) at Week 12 | -21.66 (-24.94 to -18.38) | -1.42 (-5.55 to 2.70) |
Serum HDL-C levels measured by photometry after precipitation at baseline and after 12 weeks of study drug administration.
| Percentage Change | Ezetimibe | Placebo |
|---|---|---|
| Percentage Change From Baseline High-density Lipoprotein Cholesterol (HDL-C) at Week 12 | 2.11 (-2.27 to 6.48) | 1.41 (-4.14 to 6.96) |
Serum Non-HDL-C calculated at baseline and after 12 weeks of study drug administration. Non-HDL-C values were calculated as follows: Non-HDL-C (mg/dL) = TC - HDL-C.
| Percentage Change | Ezetimibe | Placebo |
|---|---|---|
| Percentage Change From Baseline in Non-HDL-C at Week 12 | -25.47 (-28.45 to -22.49) | 0.28 (-3.52 to 4.08) |
Serum TG levels measured using enzymatic methods at baseline and after 12 weeks of study drug.
| Percentage change | Ezetimibe | Placebo |
|---|---|---|
| Percentage Change From Baseline in Triglycerides (TG) at Week 12 | -6.23 (-12.73 to 0.75) | 8.44 (-2.03 to 20.03) |
Serum LDL-C levels calculated at baseline and after 2 weeks of study drug administration. LDL-C were calculated by the method of Friedewald equation, LDL-C = Total Cholesterol (TC) - (High-density lipoprotein cholesterol \[HDL-C\] + triglyceride \[TG\]/5).
| Percentage Change | Ezetimibe | Placebo |
|---|---|---|
| Percent Change From Baseline in LDL-C at Week 2 | -24.75 (-27.80 to -21.69) | 0.23 (-3.74 to 4.20) |
Serum LDL-C levels calculated at baseline and after 4 weeks of study drug administration. LDL-C were calculated by the method of Friedewald equation, LDL-C = Total Cholesterol (TC) - (High-density lipoprotein cholesterol \[HDL-C\] + triglyceride \[TG\]/5).
| Percentage Change | Ezetimibe | Placebo |
|---|---|---|
| Percent Change From Baseline in LDL-C at Week 4 | -26.93 (-29.81 to -24.05) | -2.99 (-6.66 to 0.68) |
Serum LDL-C levels calculated at baseline and after 8 weeks of study drug administration. LDL-C were calculated by the method of Friedewald equation, LDL-C = Total Cholesterol (TC) - (High-density lipoprotein cholesterol \[HDL-C\] + triglyceride \[TG\]/5).
| Percentage Change | Ezetimibe | Placebo |
|---|---|---|
| Percent Change From Baseline in LDL-C at Week 8 | -27.22 (-30.30 to -24.15) | 0.49 (-3.46 to 4.43) |
Serum TC levels measured using enzymatic methods at baseline and after 2 weeks of study drug administration.
| Percentage Change | Ezetimibe | Placebo |
|---|---|---|
| Percentage Change From Baseline in TC at Week 2 | -18.69 (-21.21 to -16.18) | 1.40 (-1.83 to 4.63) |
Serum TC levels measured using enzymatic methods at baseline and after 4 weeks of study drug administration.
| Percentage Change | Ezetimibe | Placebo |
|---|---|---|
| Percentage Change From Baseline in TC at Week 4 | -20.57 (-23.05 to -18.08) | -0.29 (-3.45 to 2.86) |
Serum TC levels measured using enzymatic methods at baseline and after 8 weeks of study drug administration.
| Percentage Change | Ezetimibe | Placebo |
|---|---|---|
| Percentage Change From Baseline in TC at Week 8 | -20.84 (-23.40 to -18.27) | 0.54 (-2.73 to 3.81) |
Serum HDL-C levels measured by photometry after precipitation at baseline and after 2 weeks of study drug administration.
| Percentage Change | Ezetimibe | Placebo |
|---|---|---|
| Percentage Change From Baseline HDL-C at Week 2 | 0.01 (-4.28 to 4.30) | 0.96 (-4.51 to 6.43) |
Serum HDL-C levels measured by photometry after precipitation at baseline and after 4 weeks of study drug administration.
| Percentage Change | Ezetimibe | Placebo |
|---|---|---|
| Percentage Change From Baseline HDL-C at Week 4 | 0.86 (-3.69 to 5.42) | 0.33 (-5.54 to 6.19) |
Serum HDL-C levels measured by photometry after precipitation at baseline and after 8 weeks of study drug administration.
| Percentage Change | Ezetimibe | Placebo |
|---|---|---|
| Percentage Change From Baseline HDL-C at Week 8 | 1.41 (-2.95 to 5.77) | -0.52 (-6.04 to 5.00) |
Serum Non-HDL-C calculated at baseline and after 2 weeks of study drug administration. Non-HDL-C values were calculated as follows: Non-HDL-C (mg/dL) = TC - HDL-C.
| Percentage Change | Ezetimibe | Placebo |
|---|---|---|
| Percentage Change From Baseline in Non-HDL-C at Week 2 | -22.54 (-25.41 to -19.67) | 1.64 (-2.03 to 5.30) |
Serum Non-HDL-C calculated at baseline and after 4 weeks of study drug administration. Non-HDL-C values were calculated as follows: Non-HDL-C (mg/dL) = TC - HDL-C.
| Percentage Change | Ezetimibe | Placebo |
|---|---|---|
| Percentage Change From Baseline in Non-HDL-C at Week 4 | -24.94 (-27.75 to -22.14) | -0.33 (-3.88 to 3.22) |
Serum Non-HDL-C calculated at baseline and after 8 weeks of study drug administration. Non-HDL-C values were calculated as follows: Non-HDL-C (mg/dL) = TC - HDL-C.
| Percentage Change | Ezetimibe | Placebo |
|---|---|---|
| Percentage Change From Baseline in Non-HDL-C at Week 8 | -25.41 (-28.37 to -22.45) | 1.14 (-2.63 to 4.92) |
Serum TG levels measured using enzymatic methods at baseline and after 2 weeks of study drug administration.
| Percentage Change | Ezetimibe | Placebo |
|---|---|---|
| Percentage Change From Baseline in TG at Week 2 | -3.90 (-10.66 to 3.37) | 5.83 (-4.76 to 17.59) |
Serum TG levels measured using enzymatic methods at baseline and after 4 weeks of study drug administration.
| Percentage Change | Ezetimibe | Placebo |
|---|---|---|
| Percentage Change From Baseline in TG at Week 4 | -5.54 (-11.05 to 0.31) | 9.65 (0.60 to 19.53) |
Serum TG levels measured using enzymatic methods at baseline and after 8 weeks of study drug administration.
| Percentage Change | Ezetimibe | Placebo |
|---|---|---|
| Percentage Change From Baseline in TG at Week 8 | -9.99 (-16.28 to -3.21) | -1.38 (-11.02 to 9.31) |
Serum Apo A-I levels measured at baseline and after 12 weeks of study drug administration.
| Percentage Change | Ezetimibe | Placebo |
|---|---|---|
| Percentage Change From Baseline in Apolipoprotein A-I (Apo A-I) at Week 12 | 1.80 (-1.86 to 5.46) | 3.71 (-0.87 to 8.30) |
Serum TC:HDL-C Ratio calculated at baseline and after 2 weeks of study drug administration.
| Percentage Change | Ezetimibe | Placebo |
|---|---|---|
| Percentage Change From Baseline in TC:HDL-C Ratio at Week 2 | -17.21 (-21.08 to -13.34) | 2.56 (-2.37 to 7.48) |
Serum TC:HDL-C Ratio calculated at baseline and after 4 weeks of study drug administration.
| Percentage Change | Ezetimibe | Placebo |
|---|---|---|
| Percentage Change From Baseline in TC:HDL-C Ratio at Week 4 | -19.36 (-23.16 to -15.56) | 1.48 (-3.30 to 6.25) |
Serum TC:HDL-C Ratio calculated at baseline and after 8 weeks of study drug administration.
| Percentage Change | Ezetimibe | Placebo |
|---|---|---|
| Percentage Change From Baseline in TC:HDL-C Ratio at Week 8 | -20.07 (-24.20 to -15.94) | 3.41 (-1.87 to 8.70) |
Serum TC:HDL-C Ratio calculated at baseline and after 12 weeks of study drug administration.
| Percentage Change | Ezetimibe | Placebo |
|---|---|---|
| Percentage Change From Baseline in TC:HDL-C Ratio at Week 12 | -21.09 (-24.98 to -17.19) | 1.20 (-3.70 to 6.11) |
Serum LDL-C:HDL-C Ratio calculated at baseline and after 2 weeks of study drug administration.
| Percentage Change | Ezetimibe | Placebo |
|---|---|---|
| Percentage Change From Baseline in LDL-C:HDL-C Ratio at Week 2 | -23.35 (-27.69 to -19.01) | 1.15 (-4.35 to 6.65) |
Serum LDL-C:HDL-C Ratio calculated at baseline and after 4 weeks of study drug administration.
| Percentage Change | Ezetimibe | Placebo |
|---|---|---|
| Percentage Change From Baseline in LDL-C:HDL-C Ratio at Week 4 | -25.72 (-30.12 to -21.33) | -0.57 (-6.14 to 5.00) |
Serum LDL-C:HDL-C Ratio calculated at baseline and after 8 weeks of study drug administration.
| Percentage Change | Ezetimibe | Placebo |
|---|---|---|
| Percentage Change From Baseline in LDL-C:HDL-C Ratio at Week 8 | -26.43 (-31.21 to -21.66) | 2.87 (-3.28 to 9.02) |
Serum LDL-C:HDL-C Ratio calculated at baseline and after 12 weeks of study drug administration.
| Percentage Change | Ezetimibe | Placebo |
|---|---|---|
| Percentage Change From Baseline in LDL-C:HDL-C Ratio at Week 12 | -28.01 (-32.65 to -23.36) | 0.34 (-5.57 to 6.25) |
Serum Apo B:Apo A-I Ratio calculated at baseline and after 12 weeks of study drug administration
| Percentage Change | Ezetimibe | Placebo |
|---|---|---|
| Percentage Change From Baseline in Apo B:Apo A-I Ratio at Week 12 | -22.16 (-26.13 to -18.19) | -2.87 (-7.84 to 2.09) |
Plasma hs-CRP measured at baseline and after 4 weeks of study drug administration.
| Percentage Change | Ezetimibe | Placebo |
|---|---|---|
| Percentage Change From Baseline in High-sensitivity C-reactive Protein (Hs-CRP) at Week 4 | 10.00 (-15.65 to 43.45) | 56.11 (7.68 to 126.32) |
Plasma hs-CRP measured at baseline and after 12 weeks of study drug administration.
| Percentage Change | Ezetimibe | Placebo |
|---|---|---|
| Percentage Change From Baseline in High-sensitivity C-reactive Protein (Hs-CRP) at Week 12 | 9.35 (-13.47 to 38.19) | -7.92 (-33.48 to 27.46) |
Plasma sitosterol measured at baseline and after 2 weeks of study drug administration.
| Percentage Change | Ezetimibe | Placebo |
|---|---|---|
| Percent Change From Baseline in Sitosterol at Week 2 | -50.20 (-54.65 to -45.76) | -0.59 (-6.26 to 5.08) |
Plasma sitosterol measured at baseline and after 4 weeks of study drug administration.
| Percentage Change | Ezetimibe | Placebo |
|---|---|---|
| Percentage Change From Baseline in Sitosterol at Week 4 | -58.82 (-63.04 to -54.61) | -0.30 (-5.52 to 4.93) |
Plasma sitosterol measured at baseline and after 8 weeks of study drug administration.
| Percentage Change | Ezetimibe | Placebo |
|---|---|---|
| Percentage Change From Baseline in Sitosterol at Week 8 | -61.59 (-66.39 to -56.78) | -0.57 (-6.69 to 5.56) |
Plasma sitosterol measured at baseline and after 12 weeks of study drug administration.
| Percentage Change | Ezetimibe | Placebo |
|---|---|---|
| Percentage Change From Baseline in Sitosterol at Week 12 | -60.65 (-67.39 to -53.92) | 2.09 (-7.01 to 11.18) |
Plasma campesterol measured at baseline and after 2 weeks of study drug administration.
| Percentage Change | Ezetimibe | Placebo |
|---|---|---|
| Percentage Change From Baseline in Campesterol at Week 2 | -53.87 (-57.99 to -49.74) | -4.38 (-9.66 to 0.90) |
Plasma campesterol measured at baseline and after 4 weeks of study drug administration.
| Percentage Change | Ezetimibe | Placebo |
|---|---|---|
| Percentage Change From Baseline in Campesterol at Week 4 | -62.27 (-66.21 to -58.32) | -4.28 (-9.20 to 0.65) |
Plasma campesterol measured at baseline and after 8 weeks of study drug administration.
| Percentage Change | Ezetimibe | Placebo |
|---|---|---|
| Percentage Change From Baseline in Campesterol at Week 8 | -66.79 (-71.21 to -62.37) | -4.19 (-9.83 to 1.45) |
Plasma campesterol measured at baseline and after 12 weeks of study drug administration.
| Percentage Change | Ezetimibe | Placebo |
|---|---|---|
| Percentage Change From Baseline in Campesterol at Week 12 | -67.59 (-73.68 to -61.50) | -2.92 (-11.15 to 5.31) |
Plasma cholestanol measured at baseline and after 2 weeks of study drug administration.
| Percentage Change | Ezetimibe | Placebo |
|---|---|---|
| Percentage Change From Baseline in Cholestanol at Week 2 | -25.44 (-30.30 to -20.59) | -7.09 (-13.29 to -0.90) |
Plasma cholestanol measured at baseline and after 4 weeks of study drug administration.
| Percentage Change | Ezetimibe | Placebo |
|---|---|---|
| Percentage Change From Baseline in Cholestanol at Week 4 | -27.40 (-31.95 to -22.85) | -1.79 (-7.42 to 3.85) |
Plasma cholestanol measured at baseline and after 8 weeks of study drug administration.
| Percentage Change | Ezetimibe | Placebo |
|---|---|---|
| Percentage Change From Baseline in Cholestanol at Week 8 | -29.19 (-33.98 to -24.39) | -0.44 (-6.44 to 5.56) |
Plasma cholestanol measured at baseline and after 12 weeks of study drug administration.
| Percentage Change | Ezetimibe | Placebo |
|---|---|---|
| Percentage Change From Baseline in Cholestanol at Week 12 | -28.71 (-34.44 to -22.99) | 3.42 (-4.07 to 10.92) |
Plasma lathosterol measured at baseline and after 2 weeks of study drug administration.
| Percentage Change | Ezetimibe | Placebo |
|---|---|---|
| Percentage Change From Baseline in Lathosterol at Week 2 | 34.07 (24.68 to 43.45) | 14.06 (2.22 to 25.90) |
Plasma lathosterol measured at baseline and after 4 weeks of study drug administration.
| Percentage Change | Ezetimibe | Placebo |
|---|---|---|
| Percentage Change From Baseline in Lathosterol at Week 4 | 33.02 (23.44 to 42.60) | 6.73 (-5.27 to 18.73) |
Plasma lathosterol measured at baseline and after 8 weeks of study drug administration.
| Percentage Change | Ezetimibe | Placebo |
|---|---|---|
| Percentage Change From Baseline in Lathosterol at Week 8 | 35.87 (26.14 to 45.61) | -0.82 (-12.99 to 11.34) |
Plasma lathosterol measured at baseline and after 12 weeks of study drug administration.
| Percentage Change | Ezetimibe | Placebo |
|---|---|---|
| Percentage Change From Baseline in Lathosterol at Week 12 | 36.62 (26.46 to 46.78) | 12.57 (-0.36 to 25.50) |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ezetimibe | — | 2/92 (2.2%) | 27/92 (29.3%) |
| Placebo | — | 0/45 (0%) | 18/45 (40%) |
| Event | Ezetimibe | Placebo |
|---|---|---|
| Epilepsy congenitalCongenital, familial and genetic disorders | 1/92 | 0/45 |
| AppendicitisInfections and infestations | 1/92 | 0/45 |
| Event | Ezetimibe | Placebo |
|---|---|---|
| HeadacheNervous system disorders | 4/92 | 6/45 |
| Abdominal painGastrointestinal disorders | 4/92 | 5/45 |
| NasopharyngitisInfections and infestations | 10/92 | 5/45 |
| DiarrhoeaGastrointestinal disorders | 1/92 | 4/45 |
| Upper respiratory tract infectionInfections and infestations | 7/92 | 1/45 |
| NauseaGastrointestinal disorders | 1/92 | 3/45 |
| VomitingGastrointestinal disorders | 2/92 | 3/45 |
| InfluenzaInfections and infestations | 5/92 | 3/45 |
| Age, Continuous(years) | Ezetimibe | Placebo | Total |
|---|---|---|---|
| Mean | 8.2 ± 1.7 | 8.5 ± 1.6 | 8.3 ± 1.6 |
| Sex: Female, Male(Participants) | Ezetimibe | Placebo | Total |
|---|---|---|---|
| Female | 52 | 27 | 79 |
| Male | 41 | 18 | 59 |
No study locations are listed for this record.
Plan to share: No
Ran from May 2009 to primary completion in Apr 2012, 34 months.
Results were first posted in May 2013, 1 year 1 month after primary completion.
Of 122 industry-sponsored phase 3 interventional studies under Hypercholesterolemia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 34 months is above that.
Counting every sponsor, half of 125 studies reached it within 18 months; a quarter within 10 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ezetimibe